InflaRx N.V. (NASDAQ:IFRX) Financings

InflaRx N.V.

Financings

RaiseDate
Public offering of ordinary shares and pre-funded warrants
Closed: US$30M raised · US$2 a share · Warrants at US$0.001 · Guggenheim Securities, LLC +2
Dealers: Guggenheim Securities, LLC (lead), H.C. Wainwright & Co. (co-lead), Lucid Capital Markets, LLC (co-lead)
Use of proceeds: Clinical development of pipeline candidates including vilobelimab and INF904, and general corporate purposes
Feb 18, 2025

Read by 6ix AI from the company's releases